The Science Case for the Planet Formation Imager (PFI)

Among the most fascinating and hotly-debated areas in contemporary astrophysics are the means by which planetary systems are assembled from the large rotating disks of gas and dust which attend a stellar birth. Although important work has already been, and is still being done both in theory and observation, a full understanding of the physics of planet formation can only be achieved by opening observational windows able to directly witness the process in action. The key requirement is then to probe planet-forming systems at the natural spatial scales over which material is being assembled. By definition, this is the so-called Hill Sphere which delineates the region of influence of a gravitating body within its surrounding environment. The Planet Formation Imager project (PFI) has crystallized around this challenging goal: to deliver resolved images of Hill-Sphere-sized structures within candidate planet-hosting disks in the nearest star-forming regions. In this contribution we outline the primary science case of PFI. For this purpose, we briefly review our knowledge about the planet-formation process and discuss recent observational results that have been obtained on the class of transition disks. Spectro-photometric and multi-wavelength interferometric studies of these systems revealed the presence of extended gaps and complex density inhomogeneities that might be triggered by orbiting planets. We present detailed 3-D radiation-hydrodynamic simulations of disks with single and multiple embedded planets, from which we compute synthetic images at near-infrared, mid-infrared, far-infrared, and sub-millimeter wavelengths, enabling a direct comparison of the signatures that are detectable with PFI and complementary facilities such as ALMA. From these simulations, we derive some preliminary specifications that will guide the array design and technology roadmap of the facility.Comment: SPIE Astronomical Telescopes and Instrumentation conference, June 2014, Paper ID 9146-120, 13 pages, 3 Figure

The science case for the Planet Formation Imager (PFI)

archiveprefix: arXiv primaryclass: astro-ph.IM eid: 914611 adsurl: http://adsabs.harvard.edu/abs/2014SPIE.9146E..11K adsnote: Provided by the SAO/NASA Astrophysics Data SystemAmong the most fascinating and hotly-debated areas in contemporary astrophysics are the means by which planetary systems are assembled from the large rotating disks of gas and dust which attend a stellar birth. Although important work has already been, and is still being done both in theory and observation, a full understanding of the physics of planet formation can only be achieved by opening observational windows able to directly witness the process in action. The key requirement is then to probe planet-forming systems at the natural spatial scales over which material is being assembled. By definition, this is the so-called Hill Sphere which delineates the region of influence of a gravitating body within its surrounding environment. The Planet Formation Imager project (PFI; http://www.planetformationimager.org) has crystallized around this challenging goal: to deliver resolved images of Hill-Sphere-sized structures within candidate planethosting disks in the nearest star-forming regions. In this contribution we outline the primary science case of PFI. For this purpose, we briefly review our knowledge about the planet-formation process and discuss recent observational results that have been obtained on the class of transition disks. Spectro-photometric and multi-wavelength interferometric studies of these systems revealed the presence of extended gaps and complex density inhomogeneities that might be triggered by orbiting planets. We present detailed 3-D radiation-hydrodynamic simulations of disks with single and multiple embedded planets, from which we compute synthetic images at near-infrared, mid-infrared, far-infrared, and sub-millimeter wavelengths, enabling a direct comparison of the signatures that are detectable with PFI and complementary facilities such as ALMA. From these simulations, we derive some preliminary specifications that will guide the array design and technology roadmap of the facility

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Planet Formation Imager (PFI): science vision and key requirements

The Planet Formation Imager (PFI) project aims to provide a strong scientific vision for ground-based optical astronomy beyond the upcoming generation of Extremely Large Telescopes. We make the case that a breakthrough in angular resolution imaging capabilities is required in order to unravel the processes involved in planet formation. PFI will be optimised to provide a complete census of the protoplanet population at all stellocentric radii and over the age range from 0.1 to ~100 Myr. Within this age period, planetary systems undergo dramatic changes and the final architecture of planetary systems is determined. Our goal is to study the planetary birth on the natural spatial scale where the material is assembled, which is the "Hill Sphere" of the forming planet, and to characterise the protoplanetary cores by measuring their masses and physical properties. Our science working group has investigated the observational characteristics of these young protoplanets as well as the migration mechanisms that might alter the system architecture. We simulated the imprints that the planets leave in the disk and study how PFI could revolutionise areas ranging from exoplanet to extragalactic science. In this contribution we outline the key science drivers of PFI and discuss the requirements that will guide the technology choices, the site selection, and potential science/technology tradeoffs.S.K. acknowledges support from an STFC Rutherford Fellowship (ST/J004030/1) and Philip Leverhulme Prize (PLP-2013-110). Part of this work was carried out at the Jet Propulsion Laboratory, California Institute of Technology, under a contract with the National Aeronautics and Space Administration

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Optical assembly of bio-hybrid micro-robots

# The Author(s) 2015. This article is published with open access at Springerlink.com Abstract The combination of micro synthetic structures with bacterial flagella motors represents an actual trend for the construction of self-propelled micro-robots. The development of methods for fabrication of these bacteria-based robots is a first crucial step towards the realization of functional minia-ture and autonomous moving robots. We present a novel scheme based on optical trapping to fabricate living micro-robots. By using holographic optical tweezers that allow three-dimensional manipulation in real time, we are able to arrange the building blocks that constitute the micro-robot in a defined way. We demonstrate exemplarily that our method enables the controlled assembly of living micro-robots consisting of a rod-shaped prokaryotic bacterium and a single elongated zeolite L crystal, which are used as model of the biological and abiotic components, respectively. We present different proof-of-principle approaches for the site-selective attachment of the bacteria on the particle surface. The propul-sion of the optically assembled micro-robot demonstrates the potential of the proposedmethod as a powerful strategy for the fabrication of bio-hybrid micro-robots